How should I counsel a patient newly diagnosed with Mycoplasma genitalium infection?

Counseling a Patient with Newly Diagnosed Mycoplasma genitalium

Counsel the patient that M. genitalium is a sexually transmitted infection requiring antibiotic treatment, with first-line therapy being azithromycin 500 mg on day 1 followed by 250 mg daily for days 2-5, and emphasize that sexual partners must be treated concurrently to prevent reinfection. 1

Understanding the Infection

What is M. genitalium?

• M. genitalium is a sexually transmitted bacterium that causes urethritis in men (accounting for 10-35% of non-chlamydial non-gonococcal urethritis) and cervicitis and pelvic inflammatory disease in women (10-25% of cases). 2
• Transmission occurs through direct mucosal contact during sexual activity. 2
• Asymptomatic infections are common, but when symptomatic, men typically experience urethral discharge and dysuria, while women may have vaginal discharge, dysuria, or pelvic pain. 2

Potential Complications if Untreated

• In women, untreated infection can ascend the reproductive tract causing salpingitis, which may lead to infertility, ectopic pregnancy, and increased risk of preterm birth in pregnancy. 3
• The infection can also cause epididymitis in men and proctitis when affecting the rectum. 4

Treatment Approach

First-Line Treatment

• The recommended initial regimen is azithromycin 500 mg orally on day 1, followed by 250 mg orally daily on days 2-5. 1, 2
• This extended azithromycin course has higher cure rates (85-95% for macrolide-susceptible infections) compared to single-dose regimens. 2

The Antibiotic Resistance Challenge

• More than half of M. genitalium infections are now resistant to macrolides (75.8% in recent studies), and fluoroquinolone resistance is increasing (24.2%). 5
• If macrolide resistance is detected or suspected, moxifloxacin 400 mg daily for 7-14 days is the alternative treatment. 1, 2
• Moxifloxacin achieves approximately 82% microbiologic cure rates compared to only 41% with azithromycin regimens when resistance is present. 6

Treatment Monitoring

• Ideally, resistance testing should guide therapy, particularly for symptomatic patients, as resistance-guided treatment improves outcomes. 4, 2
• If initial azithromycin treatment fails, switch to moxifloxacin 400 mg daily for 7-14 days. 1

Partner Management

Critical Partner Notification

• All sexual partners from the past 60 days must be treated simultaneously, even if asymptomatic, to prevent reinfection and ongoing transmission. 1
• Patient confidentiality must be maintained during partner notification. 1
• Abstain from sexual activity until both patient and partner(s) complete treatment to prevent treatment failure and reinfection. 2

Special Considerations

Pregnancy and Breastfeeding

• Azithromycin remains the first-line treatment in pregnancy (same dosing: 500 mg day 1, then 250 mg days 2-5). 7
• Moxifloxacin should be avoided in pregnancy due to safety concerns. 7

Co-infections

• M. genitalium frequently occurs with other sexually transmitted infections including Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and viral infections (HPV, HIV). 3
• Testing for co-infections should be performed concurrently. 1

Follow-Up and Prevention

Test of Cure

• Tests of cure are not routinely recommended for asymptomatic persons after treatment. 4
• However, if symptoms persist after treatment, repeat testing is warranted to assess for treatment failure and guide second-line therapy. 2

Prevention Counseling

• Consistent condom use reduces transmission risk. 2
• Regular STI screening is important for sexually active individuals with multiple partners. 2
• Neither screening nor treatment is recommended for asymptomatic individuals due to unclear natural history and concerns about promoting antimicrobial resistance. 4, 8

Common Pitfalls to Avoid

• Do not use single-dose azithromycin (1-1.5 g) as it has lower cure rates than the extended 5-day regimen. 2
• Do not treat partners empirically without ensuring they complete the full course, as incomplete treatment contributes to resistance. 1
• Avoid doxycycline monotherapy as it only achieves 30-40% cure rates, though it may be used before azithromycin to reduce organism load. 2
• Be aware that moxifloxacin has specific warnings and should be reserved for macrolide-resistant or treatment-failure cases. 2